Understand psychiatric medications with clear, evidence-informed guidance from South Chesapeake Psychiatry. These articles cover how medications work, common benefits and side effects, dosing considerations, monitoring, drug interactions, and the questions clients should discuss with a psychiatric provider. Topics may include antidepressants, mood stabilizers, antipsychotics, ADHD medications, anxiety treatments, long-acting injectables, and newer options such as Cobenfy, Caplyta, Auvelity, and SPRAVATO®. Medication choice is never one-size-fits-all. Diagnosis, medical conditions, other prescriptions, previous treatment response, tolerability, pregnancy considerations, substance use, and personal goals can all affect the safest plan. This content is for education and should not be used to start, stop, or change medication without professional guidance. Our Chesapeake, Virginia practice provides psychiatric evaluations and ongoing medication management for adults across Hampton Roads. Follow the related service link on an article to learn more about the appropriate care pathway, or schedule an appointment for an individualized review of symptoms, history, risks, and treatment options.
A new class of compounds aims to harness brain plasticity without hallucinogenic effects. Justin Ray, MSN, PMHNP-BC of South Chesapeake Psychiatry examines psychoplastogens and what they could mean for the future of depression treatment for patients in Chesapeake, VA and across Hampton Roads.
Side effects are not a footnote to psychiatric treatment - they are often the center of it. In this edition of The Neuropsychiatry Brief, Justin Ray, MSN, PMHNP-BC of South Chesapeake Psychiatry explains why treatment-emergent adverse events drive real-world decisions, and what that means for medication management in Chesapeake, VA.
Cannabis use has become increasingly common among people who also take prescription antidepressants. This overlap is clinically important because cannabinoids, especially cannabidiol (CBD), may alter the metabolism of certain antidepressant medications and increase the likelihood of adverse effects.
Subscribe to Justin Ray's newsletter on Linkedin : The Neuropsychiatry Brief
When I read the recent Psychiatric Times reflection on the first year of Cobenfy in real-world practice, I found myself agreeing with much of what was said because the article finally acknowledged what many of us have learned the hard way: the medication itself has not been the limiting factor. Implementation has (Weiden, 2026).
The landscape of metabolic medicine has changed significantly over the past several years, largely driven by the impact of GLP-1 receptor agonists.
Schedule an appointment today to get diagnosed, receive a prescription, and continue your journey towards mental peace.
